This enjoyable #ACR18 #fibromyalgia session is an appropriate time for a couple of periodic reminders: 1. Pain is an output of the brain (not an input) 2. Fibromyalgia is best conceptualised as a *description*, not an *explanation*

#Vasculitis oral abstract session at #ACR18: back to back abstracts on use of #leflunomide for #GCA and #PMR. Promising results on efficacy and #steroid sparing effect. Could it become a standard alternative when tocilizumab contraindicated or not available?

#ACR18 #2923: Persistence of bone marrow oedema within the same SIJ quadrant associated with structural damage at 5 years in patients with early axial SpA. @RheumNow

#ACR18 #2924 - Great work by the always-impressive Sofia Ramiro using DESIR data in early AxSpA. Early progression (2-5yrs) of syndesmophytes predicted by baseline inflammation (MRI) and damage (XR). @RheumNow https://t.co/D9aGXFUtcd

#ACR18 #2952 - Validation of a clinical risk score for NSAID toxicity. Most patients fall into intermediate category, but 5% low risk, 25% high risk: probably useful in clinic if externally validated & calculator were available at point of care. @RheumNow https://t.co/DjdaYLwuX3

#ACR18 #2954 Brave presentation from Dr Jin under pressure from a feisty Jim O’Dell in the audience. Analysis of US claims database regarding combo Rx for RA. Only 3% of MTX combo is triple therapy (cf MTX+TNFi). No evidence for change over time. @RheumNow

#ACR18 #2956 Interesting UK CPRD data on opioid prescribing presented by @MeghnaJani - UK prescribers seem to be getting the message about opioids, but work still to be done (esp regarding use of strong opioids, with are hard to transition off). @RheumNow https://t.co/LwyVVVfw8i

RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Novartis. All content chosen and distributed by RheumNow and its faculty.

Patients with elevated IL-6 baseline levels had greater response to sarilumab compared with MTX or adalimumab. #L08 https://t.co/uxMOSD2B1E @RheumNow #ACR18

• http://ow.ly/G3Yz30mjIZw

Possible efficacy with LEF/HCQ in primary SS. #L10 https://t.co/1BKglr3JSF @RheumNow #ACR18

• http://ow.ly/O4BF30mjJ2U

RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Horizon Pharma. All content chosen and distributed by RheumNow and its faculty.

IXE efficacious in r-axSpA at Week 16 in TNF failure pts. #L12 https://t.co/MCpXDj9Z2o @RheumNow #ACR18

• http://ow.ly/26Eo30mjJ4t

SEC shows efficacy in AS over 5 years. #L13 https://t.co/JQFdYlA3ku @RheumNow #ACR18

• http://ow.ly/bfHU30mjJ8a

US can be used to reliably identify structural and inflammatory changes in knee OA – often earlier or better than plain radiography. https://t.co/MSp2QlqSFP @RheumNow #ACR18 #2909

• http://ow.ly/7AaV30meQug

RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Eli Lilly and Company. All content chosen and distributed by RheumNow and its faculty.